While CRMP2 levels are not correlated with clinical outcomes of cancer patients [15,27], the significantly increased nuclei-localized pCRMP2 in advanced tumors is suggested to contribute to cancer progression and thus is significantly associated with lower survival rate [27,32]. This evidence concerns the gene DPYSL2 and cancer.